AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39582975 — intervention group
Group type: EXPERIMENTAL
Intervention: PMI-targeted pressure support setting strategy
Number of subjects: 0
Study 39582975 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume/respiratory rate-targeted group
Number of subjects: 0
Study 39583146 — intervention group
Group type: EXPERIMENTAL
Intervention: CareSTEPS intervention (n=87)
Number of subjects: 174
Study 39583146 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=87)
Number of subjects: 174
Study 39583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates identified based on IPC criteria
Number of subjects: 2739
Study 39583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with BSA >10%
Number of subjects: 2739
Study 39583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with history of psoriasis affecting special areas
Number of subjects: 2739
Study 39583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with prior use of topical therapy
Number of subjects: 2739
Study 39583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with PASI scores ≤12
Number of subjects: 2739
Study 39583653 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue ITI with efmoroctocog alfa (rFVIIIFc) within 60 weeks
Number of subjects: 16
Study 39583653 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue ITI with efmoroctocog alfa (rFVIIIFc)
Number of subjects: 16
Study 39583881 — intervention group
Group type: EXPERIMENTAL
Intervention: History of catheterization (IUC)
Number of subjects: 196
Study 39583881 — intervention group
Group type: COMPARATOR
Intervention: No history of catheterization (Control)
Number of subjects: 196
Study 39583902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-dry (HD) conditions (40°C, 19% relative humidity)
Number of subjects: 12
Study 39583902 — intervention group
Group type: COMPARATOR
Intervention: Warm-wet (WW) conditions (30°C, 77% relative humidity)
Number of subjects: 12
Study 39583952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg IV every 6 weeks) plus Nivolumab (240 mg IV every 2 weeks)
Number of subjects: 8
Study 39583953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 3635
Study 39583953 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life scores
Number of subjects: 3635
Study 39583953 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel hormonal therapies
Number of subjects: 3635
Study 39584139 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg enterally once daily for 7 days
Number of subjects: 70
Study 39584139 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg intravenously every 6-8 hours for 7 days
Number of subjects: 70
Study 39584139 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 70
Study 39584139 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 70
Study 39584183 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transorbital alternating current stimulation (rtACS)
Number of subjects: 16
Study 39584183 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 16
Study 39584210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient-clinician relationship
Number of subjects: 52
Study 39584210 — intervention group
Group type: COMPARATOR
Intervention: Limited patient-clinician relationship
Number of subjects: 52
Study 39584261 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA+ICA
Number of subjects: 688
Study 39584261 — intervention group
Group type: COMPARATOR
Intervention: ICA only
Number of subjects: 688
Study 39584292 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered AdapTango dance (20 min, biweekly for 8 weeks)
Number of subjects: 52
Study 39584292 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (45 min, biweekly for 8 weeks)
Number of subjects: 52
Study 39584292 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered AdapTango dance
Number of subjects: 52
Study 39584292 — intervention group
Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 52
Study 39584292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study 39584361 — intervention group
Group type: EXPERIMENTAL
Intervention: Management for OL including surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention.
Number of subjects: 0
Study 39584361 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate biomarkers and chemoprevention agents.
Number of subjects: 0
Study 39584380 — intervention group
Group type: EXPERIMENTAL
Intervention: C10 monoclonal antibody (mAb) targeting SARS-CoV-2
Number of subjects: 0
Study 39584380 — intervention group
Group type: EXPERIMENTAL
Intervention: C10-based Chimeric Antigen Receptor (CAR)-T cells
Number of subjects: 0
Study 39584464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) approach with regular text messages for 3 months
Number of subjects: 76
Study 39584464 — intervention group
Group type: COMPARATOR
Intervention: Control group with interdental brushing instructions only at baseline and follow-up
Number of subjects: 76
Study 39584557 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT)
Number of subjects: 110
Study 39584557 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 110
Study 39584789 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) 45 mg/m2, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO)
Number of subjects: 146
Study 39584867 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation intensity
Number of subjects: 0
Study 39584867 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39584920 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk metals and metalloids
Number of subjects: 0
Study 39585012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX)
Number of subjects: 27
Study 39585012 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.7% choline salicylate (CHS)
Number of subjects: 27
Study 39585012 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) with no intervention
Number of subjects: 27
Study 39585174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 30
Study 39585174 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study 39585339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + BMS986205 (IDO-inhibitor)
Number of subjects: 42
Study 39585339 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive surgical timing
Number of subjects: 42
Study 39585451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Low-No Carbohydrates (SL-NCHO)
Number of subjects: 42
Study 39585451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep High-Low Glycemic Index (SH-LGI)
Number of subjects: 42
Study 39585451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep High-High Glycemic Index (SH-HGI)
Number of subjects: 42
Study 39585521 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 272
Study 39585605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-realistic clinical simulation during baseline visit
Number of subjects: 0
Study 39585605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-realistic clinical simulation during drug administration
Number of subjects: 0
Study 39585605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-realistic clinical simulation during home nursing scenario
Number of subjects: 0
Study 39585668 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of women with epilepsy (WWE)
Number of subjects: 298
Study 39585668 — intervention group
Group type: COMPARATOR
Intervention: Children of healthy women (HW)
Number of subjects: 298
Study 39585668 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation during the first 12 weeks of pregnancy
Number of subjects: 298
Study 39585696 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized CRC screening outreach intervention (mailed fecal immunochemical testing and patient navigation)
Number of subjects: 4002
Study 39585696 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy after positive FIT results
Number of subjects: 4002
Study 39585696 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of advanced colorectal neoplasia
Number of subjects: 4002
Study 39585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 0
Study 39585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner family caregivers
Number of subjects: 0
Study 39585776 — intervention group
Group type: EXPERIMENTAL
Intervention: AgingPLUS program, a 4-week psychoeducational intervention
Number of subjects: 0
Study 39585851 — intervention group
Group type: EXPERIMENTAL
Intervention: Revi System (implantable tibial neuromodulation)
Number of subjects: 151
Study 39585879 — intervention group
Group type: EXPERIMENTAL
Intervention: CENBA programme (mHealth psychoeducational intervention)
Number of subjects: 30
Study 39585879 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 39585936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (50 or 100 mg, twice per day) added to other antiplatelets
Number of subjects: 631
Study 39585936 — intervention group
Group type: COMPARATOR
Intervention: Non-cilostazol (no cilostazol added)
Number of subjects: 631
Study 39586017 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Supports intervention (emotional support, communication support, decisional support, anticipatory grief support)
Number of subjects: 444
Study 39586017 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus two brief education sessions about critical illness (Control)
Number of subjects: 444
Study 39586304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 4.0 mg
Number of subjects: 427
Study 39586304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 2.0 mg
Number of subjects: 427
Study 39586304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 1.0 mg
Number of subjects: 427
Study 39586304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5 mg
Number of subjects: 427
Study 39586304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 39586309 — intervention group
Group type: EXPERIMENTAL
Intervention: No-radioiodine group
Number of subjects: 776
Study 39586309 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone)
Number of subjects: 776
Study 39586354 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC-CM intervention with multifaceted implementation strategy package including comprehensive training, individual clinical supervision, group consultation, and centralized technical assistance
Number of subjects: 8
Study 39586354 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical assistance strategy
Number of subjects: 8
Study 39586616 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) plus azathioprine (AZA) with a 7-day steroid tapering scheme
Number of subjects: 64
Study 39586616 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) with conventional standardised steroid tapering regimen
Number of subjects: 64
Study 39586616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (IFX+AZA and AZA)
Number of subjects: 64
Study 39586754 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion or removal (LAAO) during cardiac surgery
Number of subjects: 4811
Study 39587050 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan (T-DXd)
Number of subjects: 53
Study 39587506 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider advice about gestational weight gain (GWG)
Number of subjects: 377
Study 39587506 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations about GWG
Number of subjects: 377
Study 39587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive Adaptive Training for Depression (NCAT-D) combined with SSRIs
Number of subjects: 118
Study 39587504 — intervention group
Group type: COMPARATOR
Intervention: SSRIs with Control treatment
Number of subjects: 118
Study 39587538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency deep brain stimulation (DBS) applied to bilateral ventral hippocampus for 3 months
Number of subjects: 6
Study 39587538 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 3 months
Number of subjects: 6
Study 39587593 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Ozone
Number of subjects: 24
Study 39587593 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 24
Study 39587600 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 206
Study 39587600 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 206
Study 39587610 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Home (CP@home) program
Number of subjects: 2284
Study 39587610 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 2284
Study 39587622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration platelet-rich plasma (PRP) injection
Number of subjects: 90
Study 39587622 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) injection
Number of subjects: 90
Study 39587799 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein breakfast (34 g protein)
Number of subjects: 56
Study 39587799 — intervention group
Group type: COMPARATOR
Intervention: Low protein breakfast
Number of subjects: 56
Study 39587796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (50 mg)
Number of subjects: 218
Study 39587796 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg)
Number of subjects: 218
Study 39587825 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended DAPT (75 mg clopidogrel plus 75-150 mg aspirin daily)
Number of subjects: 8250
Study 39587825 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (75-150 mg aspirin daily)
Number of subjects: 8250
Study 39587915 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for 4 weeks)
Number of subjects: 54
Study 39587915 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (control group)
Number of subjects: 54
Study 39587931 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV-NG2 (three-dose regimen)
Number of subjects: 1708
Study 39587931 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV-NG2 (two-dose regimen)
Number of subjects: 1708
Study 39587931 — intervention group
Group type: COMPARATOR
Intervention: HDCV (three-dose regimen)
Number of subjects: 1708
Study 39587931 — intervention group
Group type: COMPARATOR
Intervention: PVRV (three-dose regimen)
Number of subjects: 1708
Study 39588043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet supplemented with exogenous ketones for 4 weeks
Number of subjects: 4
Study 39588067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon-ablation of AF
Number of subjects: 102
Study 39588126 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) immediately after childbirth
Number of subjects: 0
Study 39588126 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived parental stress 6 months after discharge
Number of subjects: 0
Study 39588131 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (ibandronate)
Number of subjects: 0
Study 39588131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39588189 — intervention group
Group type: EXPERIMENTAL
Intervention: Yijinjing exercise (YJJG), conducted three times per week over a 12-week period
Number of subjects: 66
Study 39588189 — intervention group
Group type: EXPERIMENTAL
Intervention: Yijinjing exercise (YJJG)
Number of subjects: 66
Study 39588189 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), maintained ordinary activities
Number of subjects: 66
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: General neurocognitive outcomes
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ototoxicity
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic medical conditions
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital malformations
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-Deficit Hyperactivity Disorder
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra neurocognitive support
Number of subjects: 144
Study 39588212 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health outcomes
Number of subjects: 144
Study 39588375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 5280
Study 39588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Workload measured by electronic note count
Number of subjects: 2318
Study 39588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Years since training
Number of subjects: 2318
Study 39588974 — intervention group
Group type: EXPERIMENTAL
Intervention: EsoGuard (EG) assay on samples collected nonendoscopically with the EsoCheck (EC) device
Number of subjects: 180
Study 39588974 — intervention group
Group type: COMPARATOR
Intervention: EsoGuard (EG) assay
Number of subjects: 180
Study 39588987 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS051 1,500 mg
Number of subjects: 50
Study 39588987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 39588987 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose groups of ADS051
Number of subjects: 50
Study 39588987 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS051
Number of subjects: 50
Study 39589133 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 25 mg (n = 51)
Number of subjects: 128
Study 39589133 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 50 mg (n = 52)
Number of subjects: 128
Study 39589133 — intervention group
Group type: COMPARATOR
Intervention: Complex ART regimen (n = 25)
Number of subjects: 128
Study 39589133 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 25 mg
Number of subjects: 128
Study 39589133 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 50 mg
Number of subjects: 128
Study 39589133 — intervention group
Group type: COMPARATOR
Intervention: Complex ART regimen
Number of subjects: 128
Study 39589133 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC + LEN (both dosing regimens)
Number of subjects: 128
Study 39589151 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/Perth/16/2009 (H3N2) virus
Number of subjects: 8
Study 39589151 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study 39589250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural percutaneous US volume flow (VF) measurements before and after balloon dilation.
Number of subjects: 100
Study 39589250 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural VF measurements after angioplasty.
Number of subjects: 100
Study 39589250 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher VF at completion of angioplasty.
Number of subjects: 100
Study 39589314 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS) with 2 mL sulfur hexafluoride lipid-type A microspheres (Lumason) per lesion
Number of subjects: 40
Study 39589314 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS) for lesions ≥ 2 cm
Number of subjects: 40
Study 39589314 — intervention group
Group type: COMPARATOR
Intervention: Hepatobiliary agent MRI (HBA-MRI)
Number of subjects: 40
Study 39589314 — intervention group
Group type: COMPARATOR
Intervention: Hepatobiliary agent MRI (HBA-MRI) for lesions ≥ 2 cm
Number of subjects: 40
Study 39589314 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for all lesions
Number of subjects: 40
Study 39589314 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for lesions ≥ 2 cm
Number of subjects: 40
Study 39589370 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 592
Study 39589370 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 592
Study 39589559 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based virtual reality relaxation (SVR)
Number of subjects: 99
Study 39589559 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care and guided imagery leaflets)
Number of subjects: 99
Study 39589664 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate solution (ALN-S)
Number of subjects: 170
Study 39589664 — intervention group
Group type: COMPARATOR
Intervention: Alendronate tablet (ALN-T)
Number of subjects: 170
Study 39589664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ALN-S and ALN-T
Number of subjects: 170
Study 39589666 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic nab-paclitaxel monotherapy
Number of subjects: 1168
Study 39589666 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic nab-paclitaxel-based combination therapy
Number of subjects: 1168
Study 39589666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ≥ 4 treatment cycles
Number of subjects: 1168
Study 39589672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-labeled fluoroethyltyrosine
Number of subjects: 33
Study 39589690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarlatamab (0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 mg) administered every 2 weeks (Q2W) with a step dose regimen starting at 3 mg; infused over 1 hour.
Number of subjects: 203
Study 39589722 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous exercise group (n=22)
Number of subjects: 44
Study 39589722 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous exercise group (n=22)
Number of subjects: 44